Nektar Therapeutics vs Xilio Therapeutics
NKTR and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTR and XLO compare
Nektar Therapeutics is the larger company, worth 27 times as much as Xilio Therapeutics ($1.3B against $46.7M).
Xilio Therapeutics grew revenue faster over the last twelve months (73.0% versus −43.9% for Nektar Therapeutics).
Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.9% compared with −297% at Nektar Therapeutics.
Xilio Therapeutics scores higher on the StockData Score (11 against 9 for Nektar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTR | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $46.7M |
| Share price | $37.27 | $8.07 |
| Change, 1 year | −35.4% | −25.4% |
| Change, 5 years | −78.9% | −97.5% |
| Beta (5Y) | 2.06 | 0.89 |
| Employees | 63 | 76 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 23.0× | 0.8× (better) |
| P/B | 1.5× | 0.7× (better) |
| FCF yield | −16.4% (better) | −123% |
| Fair value | – | $31.67 |
| Margin of safety | – | 74.5% |
| Growth | ||
| Revenue growth (TTM) | −43.9% | 73.0% (better) |
| Revenue growth, 5Y average | −18.4% | – |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −254% | −74.9% (better) |
| Net margin | −297% | −20.9% (better) |
| FCF margin | −378% | −105% (better) |
| Return on equity | −35.1% (better) | −38.2% |
| Return on invested capital | −441% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.00 (better) | 4.72 |
| Altman Z-score | −0.89 (better) | −3.87 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 58.9% |
| Held by insiders | 0.46% | – |
| Insider net buying, 12 months | −$2.2M | $38.3K (better) |
| Short interest, % of float | 19.9% | – |
Go deeper
- NKTR stock overview
- NKTR income statement
- NKTR valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.